Stromal biology and therapy in pancreatic cancer

By A. Neesse, P. Michl, K. Frese, C. Feig, N. Cook, Michael A. Jacobetz, M. Lolkema, M. Buchholz, K. Olive, T. Gress and 1 more. Gut, 2010

771 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. (2011, background): “Although these preclinical results were compelling in the athymic mouse, it has been noted that the mouse stromal cells may be transformed in the presence of human xenograft.(31,32) Other existing models of PDA (eg, Kras mutations that harbor similar precancerous lesions as humans) may be needed to ”
Cancer-Associated Fibroblasts: Their Characteristics and Their Roles in Tumor Growth (2015, background): “However, CAFs are relatively rare in brain, renal, and ovarian cancers [21–29].”
Fibroblast heterogeneity in the cancer wound (2014, background): “For example, breast, prostate, and pancreatic cancers contain high numbers of CAFs, whereas brain, renal, and ovarian cancers demonstrate fewer (Neesse et al., 2011; Smith et al., 2013).”
KRAS: feeding pancreatic cancer proliferation (2014, positive): “PDAC exhibits characteristically low vascular density and a dense stromal surrounding that, in addition to hindering the delivery of therapeutics and contributing to overall PDAC aggressiveness [35], aids in the formation of numerous hypoxic regions [35,36].”